INSTRUMENTS ET MEDICAMENTS DE FRANCE : revenue, balance sheet and financial ratios

INSTRUMENTS ET MEDICAMENTS DE FRANCE is a French company founded 69 years ago, specialized in the sector Ingénierie, études techniques. Based in RAYOL-CANADEL-SUR-MER (83820), this company of category PME shows in 2024 a revenue of 341 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - INSTRUMENTS ET MEDICAMENTS DE FRANCE (SIREN 572231983)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 341 336 € 359 783 € 389 635 € 381 767 € 374 286 € 368 229 € 576 916 € 850 970 € 857 886 €
Net income 52 830 € 65 735 € 151 816 € 143 989 € 139 444 € 166 144 € 5 170 566 € 178 096 € 130 278 €
EBITDA 84 308 € 65 679 € 157 711 € 149 371 € 144 077 € -159 890 € -1 150 € 211 955 € 151 818 €
Net margin 15.5% 18.3% 39.0% 37.7% 37.3% 45.1% 896.2% 20.9% 15.2%

Revenue and income statement

In 2024, INSTRUMENTS ET MEDICAMENTS DE FRANCE achieves revenue of 341 k€. Revenue is declining over the period 2016-2024 (CAGR: -10.9%). Slight decline of -5% vs 2023. After deducting consumption (0 €), gross margin stands at 341 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 84 k€, representing 24.7% of revenue. Positive scissor effect: EBITDA margin improves by +6.4 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 53 k€, i.e. 15.5% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

341 336 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

341 336 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

84 308 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

98 714 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

52 830 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

24.7%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 144%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 33.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 11.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

144.335%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

38.724%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

11.199%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

33.795

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

55.9%

Solvency indicators evolution
INSTRUMENTS ET MEDICAMENTS DE FRANCE

Sector positioning

Debt ratio
144.34 2024
2022
2023
2024
Q1: 0.0
Med: 8.24
Q3: 42.82
Average +50 pts over 3 years

In 2024, the debt ratio of INSTRUMENTS ET MEDICAMENT... (144.34) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
38.72% 2024
2022
2023
2024
Q1: 11.26%
Med: 37.88%
Q3: 61.35%
Good -24 pts over 3 years

In 2024, the financial autonomy of INSTRUMENTS ET MEDICAMENT... (38.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
33.8 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.9 years
Average +47 pts over 3 years

In 2024, the repayment capacity of INSTRUMENTS ET MEDICAMENT... (33.80) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 444.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 56.3x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

444.275

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

56.285

Liquidity indicators evolution
INSTRUMENTS ET MEDICAMENTS DE FRANCE

Sector positioning

Liquidity ratio
444.27 2024
2022
2023
2024
Q1: 148.99
Med: 229.96
Q3: 405.09
Excellent +44 pts over 3 years

In 2024, the liquidity ratio of INSTRUMENTS ET MEDICAMENT... (444.27) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
56.28x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 2.04x
Excellent

In 2024, the interest coverage of INSTRUMENTS ET MEDICAMENT... (56.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 78 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 37 days. The gap of 41 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 89 days of revenue, i.e. 84 k€ to permanently finance. Notable WCR improvement over the period (-79%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

84 440 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

78 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

37 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

89 j

WCR and payment terms evolution
INSTRUMENTS ET MEDICAMENTS DE FRANCE

Positioning of INSTRUMENTS ET MEDICAMENTS DE FRANCE in its sector

Comparison with sector Ingénierie, études techniques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 28 648€ to 227 979€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
28k€ 75k€ 227k€
75 703 € Range: 28 648€ - 227 979€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Ingénierie, études techniques)

Compare INSTRUMENTS ET MEDICAMENTS DE FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Ingénierie, études techniques

Frequently asked questions about INSTRUMENTS ET MEDICAMENTS DE FRANCE

What is the revenue of INSTRUMENTS ET MEDICAMENTS DE FRANCE ?

The revenue of INSTRUMENTS ET MEDICAMENTS DE FRANCE in 2024 is 341 k€.

Is INSTRUMENTS ET MEDICAMENTS DE FRANCE profitable?

Yes, INSTRUMENTS ET MEDICAMENTS DE FRANCE generated a net profit of 53 k€ in 2024.

Where is the headquarters of INSTRUMENTS ET MEDICAMENTS DE FRANCE ?

The headquarters of INSTRUMENTS ET MEDICAMENTS DE FRANCE is located in RAYOL-CANADEL-SUR-MER (83820), in the department Var.

Where to find the tax return of INSTRUMENTS ET MEDICAMENTS DE FRANCE ?

The tax return of INSTRUMENTS ET MEDICAMENTS DE FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does INSTRUMENTS ET MEDICAMENTS DE FRANCE operate?

INSTRUMENTS ET MEDICAMENTS DE FRANCE operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.